Do analysts recommend FEED or VVOS?

Vivos Therapeutics has a consensus target price of $2.80, indicating a potential upside of 1,890.05%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media favor FEED or VVOS?

In the previous week, Nanovibronix had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for Nanovibronix and 3 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 1.00 beat Nanovibronix's score of 0.95 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanovibronix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate FEED or VRAX?

Virax Biolabs Group has a consensus target price of $25.00, indicating a potential upside of 950.42%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, FEED or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than Nanovibronix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanovibronix $1.93M 0.19 -$18.18M -$117.28 N/A Virax Biolabs Group $10K 190.40 -$5.02M N/A N/A

Does the media favor FEED or VRAX?

In the previous week, Nanovibronix had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 4 mentions for Nanovibronix and 3 mentions for Virax Biolabs Group. Nanovibronix's average media sentiment score of 0.95 beat Virax Biolabs Group's score of 0.27 indicating that Nanovibronix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanovibronix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Virax Biolabs Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend FEED or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FEED or GCTK more profitable?

GlucoTrack has a net margin of 0.00% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Nanovibronix -1,093.61% -60.73% -48.48% GlucoTrack N/A -2,135.52% -290.22%

Does the media prefer FEED or GCTK?

In the previous week, GlucoTrack had 7 more articles in the media than Nanovibronix. MarketBeat recorded 11 mentions for GlucoTrack and 4 mentions for Nanovibronix. Nanovibronix's average media sentiment score of 0.95 beat GlucoTrack's score of 0.40 indicating that Nanovibronix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanovibronix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GlucoTrack 1 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FEED or BTCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, FEED or BTCY?

Biotricity has higher revenue and earnings than Nanovibronix. Biotricity is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanovibronix $1.93M 0.19 -$18.18M -$117.28 N/A Biotricity $12.06M 0.12 -$14.09M -$0.14 N/A

Is FEED or BTCY more profitable?

Biotricity has a net margin of -80.42% compared to Nanovibronix's net margin of -1,093.61%. Biotricity's return on equity of 0.00% beat Nanovibronix's return on equity. Company Net Margins Return on Equity Return on Assets Nanovibronix -1,093.61% -60.73% -48.48% Biotricity -80.42% N/A -188.47%

Do analysts prefer FEED or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Nanovibronix (FEED) Competitors

$0.40 -0.09 (-17.35%)

As of 09/25/2026 01:18 PM Eastern

Compare

FEED vs. VVOS, VRAX, GCTK, BTCY, and BBLG

Should you buy Nanovibronix stock or one of its competitors? Nanovibronix's main competitors and comparable companies include Vivos Therapeutics (VVOS), Virax Biolabs Group (VRAX), GlucoTrack (GCTK), Biotricity (BTCY), and Bone Biologics (BBLG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nanovibronix compare to Vivos Therapeutics?

Nanovibronix (NASDAQ:FEED) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Nanovibronix has higher earnings, but lower revenue than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$1.93M	0.19	-$18.18M	-$117.28	N/A
Vivos Therapeutics	$17.44M	0.11	-$21.17M	-$1.90	N/A

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 12.2% of Nanovibronix shares are held by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nanovibronix has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.04, suggesting that its share price is 504% more volatile than the broader market.

In the previous week, Nanovibronix had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for Nanovibronix and 3 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 1.00 beat Nanovibronix's score of 0.95 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanovibronix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vivos Therapeutics has a consensus target price of $2.80, indicating a potential upside of 1,890.05%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Vivos Therapeutics has a net margin of -122.00% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

Summary

Vivos Therapeutics beats Nanovibronix on 9 of the 16 factors compared between the two stocks.

How does Nanovibronix compare to Virax Biolabs Group?

Nanovibronix (NASDAQ:FEED) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Virax Biolabs Group has lower revenue, but higher earnings than Nanovibronix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$1.93M	0.19	-$18.18M	-$117.28	N/A
Virax Biolabs Group	$10K	190.40	-$5.02M	N/A	N/A

In the previous week, Nanovibronix had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 4 mentions for Nanovibronix and 3 mentions for Virax Biolabs Group. Nanovibronix's average media sentiment score of 0.95 beat Virax Biolabs Group's score of 0.27 indicating that Nanovibronix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanovibronix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Virax Biolabs Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanovibronix has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Virax Biolabs Group has a net margin of 0.00% compared to Nanovibronix's net margin of -1,093.61%. Virax Biolabs Group's return on equity of 0.00% beat Nanovibronix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
Virax Biolabs Group	N/A	N/A	N/A

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 12.2% of Nanovibronix shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Virax Biolabs Group has a consensus target price of $25.00, indicating a potential upside of 950.42%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Virax Biolabs Group beats Nanovibronix on 9 of the 14 factors compared between the two stocks.

How does Nanovibronix compare to GlucoTrack?

Nanovibronix (NASDAQ:FEED) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

GlucoTrack has a net margin of 0.00% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
GlucoTrack	N/A	-2,135.52%	-290.22%

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 12.2% of Nanovibronix shares are held by company insiders. Comparatively, 5.9% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nanovibronix has higher revenue and earnings than GlucoTrack. GlucoTrack is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$1.93M	0.19	-$18.18M	-$117.28	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, GlucoTrack had 7 more articles in the media than Nanovibronix. MarketBeat recorded 11 mentions for GlucoTrack and 4 mentions for Nanovibronix. Nanovibronix's average media sentiment score of 0.95 beat GlucoTrack's score of 0.40 indicating that Nanovibronix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanovibronix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	1 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanovibronix has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Summary

Nanovibronix beats GlucoTrack on 10 of the 12 factors compared between the two stocks.

How does Nanovibronix compare to Biotricity?

Nanovibronix (NASDAQ:FEED) and Biotricity (NASDAQ:BTCY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Nanovibronix had 4 more articles in the media than Biotricity. MarketBeat recorded 4 mentions for Nanovibronix and 0 mentions for Biotricity. Nanovibronix's average media sentiment score of 0.95 beat Biotricity's score of 0.00 indicating that Nanovibronix is being referred to more favorably in the media.

Company	Overall Sentiment
Nanovibronix	Positive
Biotricity	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Biotricity has a net margin of -80.42% compared to Nanovibronix's net margin of -1,093.61%. Biotricity's return on equity of 0.00% beat Nanovibronix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
Biotricity	-80.42%	N/A	-188.47%

Biotricity has higher revenue and earnings than Nanovibronix. Biotricity is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$1.93M	0.19	-$18.18M	-$117.28	N/A
Biotricity	$12.06M	0.12	-$14.09M	-$0.14	N/A

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 12.2% of Nanovibronix shares are held by insiders. Comparatively, 1.6% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nanovibronix has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Biotricity has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Summary

Nanovibronix beats Biotricity on 9 of the 14 factors compared between the two stocks.

How does Nanovibronix compare to Bone Biologics?

Nanovibronix (NASDAQ:FEED) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

In the previous week, Nanovibronix had 3 more articles in the media than Bone Biologics. MarketBeat recorded 4 mentions for Nanovibronix and 1 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 1.82 beat Nanovibronix's score of 0.95 indicating that Bone Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nanovibronix	Positive
Bone Biologics	Very Positive

Bone Biologics has lower revenue, but higher earnings than Nanovibronix. Bone Biologics is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$1.93M	0.19	-$18.18M	-$117.28	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A

Nanovibronix has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Bone Biologics has a net margin of 0.00% compared to Nanovibronix's net margin of -1,093.61%. Bone Biologics' return on equity of -57.87% beat Nanovibronix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
Bone Biologics	N/A	-57.87%	-53.65%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 12.2% of Nanovibronix shares are owned by insiders. Comparatively, 5.0% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Nanovibronix and Bone Biologics tied by winning 6 of the 12 factors compared between the two stocks.

Get Nanovibronix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEED vs. The Competition

Export

Metric	Nanovibronix	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$374K	$5.54B	$7.29B	$13.12B
Dividend Yield	N/A	1.80%	2.52%	13.50%
P/E Ratio	0.00	25.31	276.12	25.78
Price / Sales	0.19	44.56	619.44	84.48
Price / Cash	N/A	32.96	79.23	52.93
Price / Book	0.00	5.77	10.44	6.30
Net Income	-$18.18M	$151.55M	$3.51B	$360.35M
7 Day Performance	-45.60%	-0.97%	-1.31%	-0.23%
1 Month Performance	-91.07%	-4.82%	-4.72%	-3.87%
1 Year Performance	N/A	7.60%	14.97%	5.38%

Nanovibronix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEED Nanovibronix	1.4082 of 5 stars	$0.41 -17.3%	N/A	N/A	$374K	$1.93M	N/A	20	News Coverage Short Interest Decrease Gap Up
VVOS Vivos Therapeutics	2.809 of 5 stars	$0.15 -4.9%	$2.80 +1,780.5%	-95.8%	$2.18M	$20.90M	N/A	268	Gap Up
VRAX Virax Biolabs Group	1.9263 of 5 stars	$2.52 +0.6%	$25.00 +893.6%	-84.8%	$1.99M	$10K	N/A	26	Short Interest Increase Gap Down
GCTK GlucoTrack	0.4979 of 5 stars	$2.03 -8.6%	N/A	-98.0%	$1.57M	N/A	N/A	15	Trending News Short Interest Increase High Trading Volume
BTCY Biotricity	N/A	$0.08 +6.8%	N/A	-87.9%	$1.51M	$12.06M	N/A	46	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEED) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanovibronix (FEED) Competitors

FEED vs. VVOS, VRAX, GCTK, BTCY, and BBLG

How does Nanovibronix compare to Vivos Therapeutics?

Summary

How does Nanovibronix compare to Virax Biolabs Group?

Summary

How does Nanovibronix compare to GlucoTrack?

Summary

How does Nanovibronix compare to Biotricity?

Summary

How does Nanovibronix compare to Bone Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanovibronix (FEED) Competitors

FEED vs. VVOS, VRAX, GCTK, BTCY, and BBLG

How does Nanovibronix compare to Vivos Therapeutics?

Which has preferable valuation and earnings, FEED or VVOS?

Do insiders & institutionals believe in FEED or VVOS?

Which has more volatility and risk, FEED or VVOS?

Does the media favor FEED or VVOS?

Do analysts recommend FEED or VVOS?

Is FEED or VVOS more profitable?

Summary

How does Nanovibronix compare to Virax Biolabs Group?

Which has better valuation and earnings, FEED or VRAX?

Does the media favor FEED or VRAX?

Which has more risk & volatility, FEED or VRAX?

Is FEED or VRAX more profitable?

Do institutionals & insiders believe in FEED or VRAX?

Do analysts rate FEED or VRAX?

Summary

How does Nanovibronix compare to GlucoTrack?

Is FEED or GCTK more profitable?

Do institutionals & insiders hold more shares of FEED or GCTK?

Which has stronger earnings & valuation, FEED or GCTK?

Do analysts recommend FEED or GCTK?

Does the media prefer FEED or GCTK?

Which has more volatility and risk, FEED or GCTK?

Summary

How does Nanovibronix compare to Biotricity?

Does the media prefer FEED or BTCY?

Do analysts prefer FEED or BTCY?

Is FEED or BTCY more profitable?

Which has better valuation and earnings, FEED or BTCY?

Do institutionals and insiders hold more shares of FEED or BTCY?

Which has more risk and volatility, FEED or BTCY?

Summary

How does Nanovibronix compare to Bone Biologics?

Does the media prefer FEED or BBLG?

Which has better earnings and valuation, FEED or BBLG?

Which has more volatility and risk, FEED or BBLG?

Is FEED or BBLG more profitable?

Do analysts prefer FEED or BBLG?

Do institutionals and insiders hold more shares of FEED or BBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools